» Articles » PMID: 31010257

The Potential of the Cyclotide Scaffold for Drug Development

Overview
Journal Biomedicines
Date 2019 Apr 24
PMID 31010257
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclotides are a novel class of micro-proteins (≈30-40 residues long) with a unique topology containing a head-to-tail cyclized backbone structure further stabilized by three disulfide bonds that form a cystine knot. This unique molecular framework makes them exceptionally stable to physical, chemical, and biological degradation compared to linear peptides of similar size. The cyclotides are also highly tolerant to sequence variability, aside from the conserved residues forming the cystine knot, and are orally bioavailable and able to cross cellular membranes to modulate intracellular protein-protein interactions (PPIs), both in vitro and in vivo. These unique properties make them ideal scaffolds for many biotechnological applications, including drug discovery. This review provides an overview of the properties of cyclotides and their potential for the development of novel peptide-based therapeutics. The selective disruption of PPIs still remains a very challenging task, as the interacting surfaces are relatively large and flat. The use of the cell-permeable highly constrained polypeptide molecular frameworks, such as the cyclotide scaffold, has shown great promise, as it provides unique pharmacological properties. The use of molecular techniques, such as epitope grafting, and molecular evolution have shown to be highly effective for the selection of bioactive cyclotides. However, despite successes in employing cyclotides to target PPIs, some of the challenges to move them into the clinic still remain.

Citing Articles

Plant Defense Peptides: Exploring the Structure-Function Correlation for Potential Applications in Drug Design and Therapeutics.

Shirsat H, Datt M, Kale A, Mishra M ACS Omega. 2025; 10(8):7583-7596.

PMID: 40060863 PMC: 11886644. DOI: 10.1021/acsomega.4c11339.


Advances in cyclotide research: bioactivity to cyclotide-based therapeutics.

Grover A, Singh S, Sindhu S, Lath A, Kumar S Mol Divers. 2025; .

PMID: 39862350 DOI: 10.1007/s11030-025-11113-w.


Miniprotein engineering for inhibition of PD-1/PD-L1 interaction.

Ciesiolkiewicz A, Lizandra Perez J, Skalniak L, Nocen P, Berlicki L Protein Sci. 2024; 33(8):e5106.

PMID: 39012010 PMC: 11250529. DOI: 10.1002/pro.5106.


Resistance is futile: targeting multidrug-resistant bacteria with Cys-rich cyclic polypeptides.

Mourenza A, Ganesan R, Camarero J RSC Chem Biol. 2023; 4(10):722-735.

PMID: 37799576 PMC: 10549238. DOI: 10.1039/d3cb00015j.


Lipidation of a bioactive cyclotide-based CXCR4 antagonist greatly improves its pharmacokinetic profile in vivo.

Chaudhuri D, Lu T, Jacob B, Abraham S, Shankar P, Poss M J Control Release. 2023; 359:26-32.

PMID: 37236320 PMC: 10527528. DOI: 10.1016/j.jconrel.2023.05.026.


References
1.
Daly N, Craik D . Circular proteins in plants: solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis. J Biol Chem. 2001; 276(25):22875-82. DOI: 10.1074/jbc.M101666200. View

2.
Heitz A, Hernandez J, Gagnon J, Hong T, Pham T, Nguyen T . Solution structure of the squash trypsin inhibitor MCoTI-II. A new family for cyclic knottins. Biochemistry. 2001; 40(27):7973-83. DOI: 10.1021/bi0106639. View

3.
Jennings C, West J, Waine C, Craik D, Anderson M . Biosynthesis and insecticidal properties of plant cyclotides: the cyclic knotted proteins from Oldenlandia affinis. Proc Natl Acad Sci U S A. 2001; 98(19):10614-9. PMC: 58514. DOI: 10.1073/pnas.191366898. View

4.
Lindholm P, Goransson U, Johansson S, Claeson P, Gullbo J, Larsson R . Cyclotides: a novel type of cytotoxic agents. Mol Cancer Ther. 2002; 1(6):365-9. View

5.
Rosengren K, Daly N, Plan M, Waine C, Craik D . Twists, knots, and rings in proteins. Structural definition of the cyclotide framework. J Biol Chem. 2002; 278(10):8606-16. DOI: 10.1074/jbc.M211147200. View